User profiles forHossein-Ardeschir Ghofrani
 |
Hossein Ardeschir Ghofrani
Justus-Liebig University Giessen, ECCPS, Kerckhoff-Klinik Bad Nauheim, Imperial College …
Verified email at innere.med.uni-giessen.de
Cited by 66023 |
ERS statement on chronic thromboembolic pulmonary hypertension
…, P Dorfmuller, E Fadel,HAGhofrani… - European …, 2021 - Eur Respiratory Soc
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …
Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is thought to result from incomplete
resolution of pulmonary thromboemboli that undergo organisation into fibrous tissue …
resolution of pulmonary thromboemboli that undergo organisation into fibrous tissue …
Targeting cancer with phosphodiesterase inhibitors
…, GA Banat, N Weissmann,HAGhofrani… - Expert opinion on …, 2010 - Taylor & Francis
Importance of the field: For many cancers, there has been a shift from management with
traditional, nonspecific cytotoxic chemotherapies to treatment with molecule-specific targeted …
traditional, nonspecific cytotoxic chemotherapies to treatment with molecule-specific targeted …
Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension
HAGhofrani, R Wiedemann, F Rose… - Annals of internal …, 2002 - acpjournals.org
Background: Inhalation of the stable prostacyclin analogue iloprost is being studied for
treatment of pulmonary hypertension. The selective phosphodiesterase-5 inhibitor sildenafil has …
treatment of pulmonary hypertension. The selective phosphodiesterase-5 inhibitor sildenafil has …
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
HAGhofrani, R Wiedemann, F Rose, RT Schermuly… - The Lancet, 2002 - Elsevier
Background Lung fibrosis can be complicated by pulmonary hypertension, limiting exercise
tolerance and life expectancy. Furthermore, vasodilators might cause deterioration in gas …
tolerance and life expectancy. Furthermore, vasodilators might cause deterioration in gas …
[HTML][HTML]Riociguat for the treatment of pulmonary arterial hypertension
HAGhofrani,N Galiè, F Grimminger, E Grünig… - N Engl J …, 2013 - Mass Medical Soc
Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase
2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …
2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …
[HTML][HTML]Riociguat for the treatment of chronic thromboembolic pulmonary hypertension
HAGhofrani, AM D'Armini, F Grimminger… - … England Journal of …, 2013 - Mass Medical Soc
Background Riociguat, a member of a new class of compounds (soluble guanylate cyclase
stimulators), has been shown in previous clinical studies to be beneficial in the treatment of …
stimulators), has been shown in previous clinical studies to be beneficial in the treatment of …
[HTML][HTML]Macitentan and morbidity and mortality in pulmonary arterial hypertension
…, RN Channick, M Delcroix,N Galiè,HAGhofrani… - N engl j …, 2013 - Mass Medical Soc
Background Current therapies for pulmonary arterial hypertension have been adopted on the
basis of short-term trials with exercise capacity as the primary end point. We assessed the …
basis of short-term trials with exercise capacity as the primary end point. We assessed the …
[HTML][HTML]Reversal of experimental pulmonary hypertension by PDGF inhibition
RT Schermuly, E Dony,HAGhofrani… - The Journal of …, 2005 - Am Soc Clin Investig
Progression of pulmonary hypertension is associated with increased proliferation and migration
of pulmonary vascular smooth muscle cells. PDGF is a potent mitogen and involved in …
of pulmonary vascular smooth muscle cells. PDGF is a potent mitogen and involved in …
[HTML][HTML]Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension
…, JA Barberà, AE Frost,HAGhofrani… - … England Journal of …, 2015 - Mass Medical Soc
Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …